niacinamide has been researched along with camptothecin in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 17 (80.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Kameoka, M; Kamiya, T; Kojima, K; Tanaka, Y; Tohno, Y; Yoshihara, K | 1 |
| Baas, F; Brendel, E; Buss, P; Mersmann, S; Mross, K; Reil, M; Schwartz, B; Steinbild, S; Voliotis, D | 1 |
| Baas, F; Brendel, E; Christensen, O; Gmehling, D; Mross, K; Radtke, M; Steinbild, S; Unger, C; Voliotis, D | 1 |
| Pappo, A; Paulino, AC | 1 |
| Choudhary, C; Jackson, SP; Kaidi, A; Weinert, BT | 1 |
| Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W | 1 |
| Arcaroli, J; Azad, N; Carducci, MA; Dasari, A; Diaz, LA; Donehower, RC; Hidalgo, M; Laheru, DA; McManus, M; Messersmith, WA; Quackenbush, K; Rudek, MA; Taylor, GE; Wright, JJ; Zhao, M | 1 |
| Assenat, E; Causse, A; Del Rio, M; Evrard, A; Gongora, C; Jarlier, M; Leconet, W; Martineau, P; Mazard, T; Robert, B; Simony, J; Torro, A; Vezzio-Vie, N; Ychou, M | 1 |
| Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M | 1 |
| Smith, MA | 1 |
| Gongora, C | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Burris, HA; Chen, L; Goldstein, D; Hsu, CP; Hurwitz, H; Kotasek, D; Schwartzberg, LS; Stephenson, J; Tebbutt, N; Warner, DJ | 1 |
| Cervantes, A; Ciardiello, F; Jego, V; Laffranchi, B; Macarulla, T; Martinelli, E; Prenen, H; Roselló, S; Tabernero, J; Tejpar, S; Troiani, T; Van Cutsem, E; von Richter, O | 1 |
| Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J | 1 |
| Jian, C; Pei-hua, L; Xiao-chun, Y; Xu, L; Yuan-run, Z | 1 |
| Durmus, S; Schinkel, AH; van Hoppe, S | 1 |
| Hu, Y; Lin, A; Ma, C; Niu, Y; Shi, L; Su, Y; Zhang, C; Zhou, L; Zhu, X | 1 |
| Goto, H; Goto, S; Hamanoue, S; Iwasaki, F; Keino, D; Kitagawa, N; Miyagawa, N; Miyagi, Y; Sarashina, T; Sekiguchi, H; Shiomi, M; Sugiyama, M; Tanaka, Y; Yokosuka, T | 1 |
| Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I | 1 |
2 review(s) available for niacinamide and camptothecin
| Article | Year |
|---|---|
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Drug Interactions; Gene Expression; Hepatocytes; Humans; Inactivation, Metabolic; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Methotrexate; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Platinum Compounds; Sorafenib; Taxoids | 2016 |
7 trial(s) available for niacinamide and camptothecin
| Article | Year |
|---|---|
Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Benzenesulfonates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2003 |
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2007 |
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tissue Distribution | 2013 |
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib | 2014 |
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Middle Aged; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Panitumumab; Young Adult | 2015 |
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2015 |
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
12 other study(ies) available for niacinamide and camptothecin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Inhibition and down-regulation of poly(ADP-ribose) polymerase results in a marked resistance of HL-60 cells to various apoptosis-inducers.
Topics: Adenosine; Alkaloids; Apoptosis; Calcimycin; Camptothecin; Dactinomycin; DNA, Neoplasm; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Enzyme Inhibitors; HL-60 Cells; Humans; Niacinamide; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Staurosporine; Teniposide | 1995 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
RETRACTED: Human SIRT6 promotes DNA end resection through CtIP deacetylation.
Topics: Acetylation; Animals; Camptothecin; Carrier Proteins; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; DNA; DNA Breaks, Double-Stranded; DNA Repair; DNA, Single-Stranded; Endodeoxyribonucleases; Genomic Instability; Humans; Mice; Mutant Proteins; Niacinamide; Nuclear Proteins; Protein Binding; Recombination, Genetic; Sirtuins | 2010 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--letter.
Topics: Animals; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Humans; Neoplasm Proteins; Niacinamide; Phenylurea Compounds | 2014 |
Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--response.
Topics: Animals; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Humans; Neoplasm Proteins; Niacinamide; Phenylurea Compounds | 2014 |
[Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism].
Topics: Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Histones; Humans; Irinotecan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Sorafenib; Tumor Suppressor Protein p53 | 2015 |
Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Liberation; HT29 Cells; Humans; Male; Matrix Metalloproteinase 2; Mice, Inbred BALB C; Nanoparticles; Niacinamide; Phenylurea Compounds; Photoacoustic Techniques; Rats, Sprague-Dawley; Sorafenib; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Screening Assays, Antitumor; Drug Synergism; Female; Hepatoblastoma; Humans; Indoles; Infant; Inhibitory Concentration 50; Irinotecan; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Recurrence; Sorafenib; Sunitinib | 2017 |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib | 2017 |